Northland analyst Gus Richard raised the firm's price target on Arteris to $16 from $14 and keeps an Outperform rating on the shares. Arteris reported an in-line quarter for revenue and guided in-line, but "these numbers miss bookings and new product momentum," the analyst tells investors in a post-earnings note.